VERTANICAL’s VER-01 cannabis extract, formulated with 2.5 milligrams of THC and standardized amounts of CBD and CBG, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. The designation follows a Phase 3 clinical trial in which patients who took VER-01 reported greater mean pain reductions than participants who received opioid treatment.
The FDA awards Breakthrough Therapy designation to investigational medicines when preliminary clinical evidence indicates the drug may offer a clear improvement over existing therapies and when expedited development could help patients. The status does not equal approval; it directs the agency to provide intensive guidance and a faster review path during remaining clinical development and the eventual submission for approval.
VERTANICAL, based in Grafelfing, Germany, said the company will start additional Phase 3 trials in the United States before filing for FDA approval, and expects European regulators to authorize VER-01 soon. The company released details through PR Newswire and emphasized the product’s fixed 2.5 mg THC dose alongside specific, standardized percentages of cannabidiol (CBD) and cannabigerol (CBG). The manufacturer says the standardized profile is intended to ensure consistent dosing across production batches and clinical sites.
Company founder Dr. Clemens Fischer described the FDA designation as recognition of VER-01’s potential to offer a non-opioid option for chronic pain patients. VERTANICAL intends to use the Breakthrough pathway to accelerate remaining trials and regulatory interactions in the U.S.
Regulatory and market context
The FDA has previously approved only a small number of plant-derived and synthetic cannabinoid products. In 2018 the agency approved Epidiolex, a standardized cannabidiol medication, for two rare epilepsies; that drug contains plant-derived CBD and other defined components in a measured formulation. Dronabinol (Marinol), nabilone (Cesamet), and the liquid synthetic THC product Syndros are older approvals that rely on synthetic cannabinoids rather than standardized plant extracts.
VERTANICAL’s application differs from many existing cannabinoid prescriptions because VER-01 is a plant-derived extract with standardized ratios of multiple cannabinoids rather than a single-isolate synthetic compound. The company highlights a fixed 2.5 mg THC dose as part of a multi-cannabinoid profile intended for chronic pain patients.
Clinical evidence cited
VERTANICAL’s press release said the FDA decision followed Phase 3 results showing greater mean pain reduction with VER-01 than with opioids. The company did not publish numeric results or the trial protocol in its PR Newswire release; it said further Phase 3 trials will expand the U.S. evidence base prior to submission for approval. The Breakthrough designation typically rests on early clinical data that suggest a medicine may provide substantial improvement over available therapies, and it triggers more frequent and proactive interactions with FDA reviewers.
What Breakthrough designation does and does not do
Breakthrough status speeds communication and can shorten development timelines, but it does not change the data requirements for approval. Sponsors must still complete adequate and well-controlled trials that demonstrate safety and efficacy. VERTANICAL’s stated plan to run additional Phase 3 trials in the U.S. aligns with that requirement: the company will need to replicate findings, report full safety data, and submit a complete New Drug Application (NDA) or Biologics License Application (BLA) depending on the regulatory pathway the FDA specifies.
Implications for pain treatment and market
VERTANICAL positions VER-01 as a non-opioid alternative for chronic pain, a clinical priority given opioid-related overdose and dependence statistics. The company claims the Phase 3 data show greater mean pain reductions compared with opioids, which, if confirmed in subsequent trials and accepted by FDA reviewers, could support a labeled indication for pain and broaden prescriber options.
Analysts and clinicians will watch several aspects closely in upcoming disclosures: the size of the treatment effect measured in validated pain scales, duration of benefit, adverse event profiles compared with opioids, and consistency of cannabinoid content across manufacturing batches. VERTANICAL’s emphasis on standardized CBD and CBG percentages addresses concerns regulators often raise about variability in plant-derived products.
Next steps
VERTANICAL plans additional Phase 3 trials in the United States and anticipates European authorization processes to proceed soon. The company has not yet released full trial data, patient numbers, or detailed safety summaries in public registries or peer-reviewed journals. Observers seeking to assess VER-01’s clinical value will look for published trial protocols, statistical results including effect sizes and confidence intervals, and safety tables that compare adverse events between treatment arms.
The FDA Breakthrough Therapy designation will give VERTANICAL more frequent and structured interactions with regulators as the company completes clinical development. That interaction can help resolve trial design questions and align on the data the FDA will require for a marketing application, but final approval will depend on subsequent trial outcomes and regulatory review.
Source: VERTANICAL press release via PR Newswire.
